Antiviral treatments are available to the 'Severely Immunosuppressed' a subset of the Clinically Vulnerable who remain at high-risk despite up to 5 vaccine doses.
๐งตwill cover how Vulnerable groups can access antiviral treatments. 1/
Early antiviral treatment is a vital tool to prevent severe outcomes in high-risk people.
Currently only a small group who have poor immunity following vaccination are allowed to access them.
Please look through this list to see if you qualify:
7. If you are told they only consider patients until day 6 or 7 refer them to this pathway.
By day 6/7 you would be limited to Remdesivir or 'off-label' (where a medicine used in a way different to that in the licence) access to the other treatments.
Weekend access is generally poor. It appears to be a postcode lottery.
We are worried about the availability of services over the upcoming 4 day Bank Holiday weekend.
Some areas will offer treatment on day 6/7, but this is far from optimal.
10/
8. If you are refused treatment and you do qualify you need to take it further try escalating within the hospital via your specialist team / PALS but be prepared to take it all the way to your local MP if all else fails by day 5.
We have heard that 10-15% of people who DO qualify can access these antiviral treatments.
Put another way, it means 85-90% can't access the antivirals.
We are highly concerned about this number!
12/
What if you are Clinically Vulnerable/50+ and DON'T qualify on the list?
The only possibility is accessing treatments via the Panoramic trial.
Lots of people can qualify for the trial but only 450 participants are added daily, of which only 225 are given the treatments.
13/
The demand has been high, due to the current surge.
However, this is currently closed for Easter...
It also appears to close over the weekends.
14/
The Panoramic trial has a screening process and either your GP, or a study nurse or doctor will assess your eligibility and ask for your consent.
If you do qualify you will have a 50:50 chance of being offered antivirals, which should arrive the next day.
15/
Even if you don't receive the antivirals you will need answer questions online for 28 days and answer 3 phone calls to discuss with the trial team on days 7, 14 & 28.
16/
We believe this constitutes health rationing.
Those 75+ should have been added to the antivirals list.
Plus, since treatments are already proven safe and effective for all Clinically Vulnerable / 50+, they should all have #Access2Antivirals through GPs and emergency GPs.
Who will get a Covid booster in 2025? Far fewer than before...
The JCVI decision means that Clinically Vulnerable people u70 and who aren't immunosuppressed lose access.
โCost-effectivenessโ prioritised over protection.
NEW CONCERNING STUDY ๐
1/๐งต
Until now, Covid vaccine policy prioritised protecting 'at risk' groups.
Their approach focuses on โcost-effectiveness,โ raising age thresholds. Not providing vaccine protection to younger Clinically Vulnerable. Itโs a deeply worrying change.
This data may have been used. 2/
Younger Clinically Vulnerable people e.g. those with chronic heart failure, COPD, or diabetes could be excluded.
The study admits data for our group is limited, meaning the most at-risk could fall through the cracks.
*It is unclear if the study was used in decision-making.*
Rosemary Gallagher MBE (Professional Lead for Infection Prevention and Control at the Royal College of Nursing) supported non-IP specialists e.g. aerosols experts "shaping guidance".
1/
"If Covid-19 was, in fact, airborne [.] it had implications for infection prevention and control guidance [.]"
"What was the NHS estate going to do to make it safe?"
"Improving the ventilation or looking at other technologies [.]." 2/
Next, possibly the best quote from Baroness Hallett this week:
โป๏ธ RETWEET if you think that Clinically Vulnerable people (those at the most risk from Covid) were economically impacted by the pandemic. โป๏ธ
The @covidinquiryuk rejected us for this module, leaving us with * NO VOICE * !!!!
1/
Clinically Vulnerable (CV) people and their families faced, and in many cases continue to face, enormous economic strain.
For many, shielding was the only safe option, but it came with serious costsโlost jobs, reduced hours, and in many cases, the inability to work at all.
2/
Without protections, CV people and their families couldnโt simply return to โbusiness as usualโ as measures lifted.
Many continued shielding, at their own expense, as they were unable to risk exposure. For some, this meant months / even years out of the workforce.
๐จCOVID INQUIRY ROUND UP (Wk 4)
Due to sickness, this week of evidence ended early.
CMO ๐ด๓ ง๓ ข๓ ท๓ ฌ๓ ณ๓ ฟ
Impact witnesses:
Ambulance, GPs, Intensive Care
Former medical director of WHSCT
National Ambulance Adviser NHS England
Intensive Care Experts and witnesses
1/
๐ด๓ ง๓ ข๓ ท๓ ฌ๓ ณ๓ ฟ The Welsh CMO, Sir Frank Atherton, spoke about "broadly accepting" advice from the now highly contentious 'IPC cell' led by Dr Lisa Ritchie.